Skip to main content
Erschienen in: International Journal of Clinical Pharmacy 3/2008

01.06.2008 | Short Research Report

Critical appraisal of apparently evidence-based written advertising in Pakistan

verfasst von: Dileep Kumar Rohra, Muhammad Umair Bashir, Ummey Aymen Khwaja, Muhammad Ressam Nazir

Erschienen in: International Journal of Clinical Pharmacy | Ausgabe 3/2008

Einloggen, um Zugang zu erhalten

Abstract

Objectives The objective of the study was to critically assess references cited in support of claims in drug advertisements. Methods Drug advertising brochures were collected from privately practicing General Practitioners from different parts of Karachi. Three blinded reviewers then categorized each reference in the brochure according to the sources viz: journals (both Medline indexed and non-indexed), medical reference books, web addresses, personal communications or testimonials, abstracts presented at symposia/conferences, WHO and National Health Guidelines, ‘data on file’ and ‘others’ (which included a diverse set of references). Each reviewer then assessed and analyzed the references further into 2 broad categories: traceable and non-traceable. Traceable references were appraised and, depending upon the claim with which the reference was attached, were classified into justifiable, inaccurate/false, exaggerated and ambiguous. Results We collected a total of 175 different brochures. Thirty-nine (22.3%) brochures did not cite any references and were not subjected to further analysis. The remaining 136 (77.7%) contained a total of 559 references. 305 (54.6%) of these references were from Medline-indexed journals; 67 (12.0%) were from non-indexed journals; 55 (9.8%) references quoted medical reference books; 27 (4.8%) references cited web addresses; 12 (2.1%) references were personal communications/testimonials; 11 (2.0%) references referred to abstracts presented at symposia/conferences; 12 (2.1%) references were from WHO and National Health Guidelines; 8 (1.4%) references were listed as ‘data on file’, while the remainder that could not be defined were classified as ‘others’ (13.1%). Out of a total of 559 references, 249 (44.5%) could not be traced. After critically analyzing the 310 traceable references, 197 (63.5%) were adjudged justifiable, 30 (9.7%) inaccurate/false, 79 (25.5%) exaggerated and 15 (4.8%) ambiguous. Conclusion Results of this study show for the first time that the claims substantiated with references in the pharmaceutical advertisements in Pakistan are highly unreliable.
Literatur
1.
Zurück zum Zitat Rohra DK, Gilani AH, Memon IK, et al. Critical evaluation of the claims made by pharmaceutical companies in drug promotional material in Pakistan. J Pharm Pharm Sci 2006;9:50–9.PubMed Rohra DK, Gilani AH, Memon IK, et al. Critical evaluation of the claims made by pharmaceutical companies in drug promotional material in Pakistan. J Pharm Pharm Sci 2006;9:50–9.PubMed
2.
Zurück zum Zitat Silverman M, Lee PR, Lydecker M. The drugging of the Third World. Int J Health Serv 1982;12:585–96.PubMedCrossRef Silverman M, Lee PR, Lydecker M. The drugging of the Third World. Int J Health Serv 1982;12:585–96.PubMedCrossRef
3.
Zurück zum Zitat Lee PR, Lurie P, Silverman MM, Lydecker M. Drug promotion and labeling in developing countries: an update. J Clin Epidemiol 1991;44 Suppl 2:S49–55. Lee PR, Lurie P, Silverman MM, Lydecker M. Drug promotion and labeling in developing countries: an update. J Clin Epidemiol 1991;44 Suppl 2:S49–55.
4.
Zurück zum Zitat Rohra DK, Jawaid A, Rehman T, Sukkurwala AQ, Palanpurwala AS, Gangwani R. Prescription of new drugs by general practitioners in Pakistan: an exploration into information sources, prescription influences and general attitudes. Pak J Med Res 2007;46:5–10. Rohra DK, Jawaid A, Rehman T, Sukkurwala AQ, Palanpurwala AS, Gangwani R. Prescription of new drugs by general practitioners in Pakistan: an exploration into information sources, prescription influences and general attitudes. Pak J Med Res 2007;46:5–10.
5.
9.
Zurück zum Zitat Gutknecht DR. Evidence-based advertising? A survey of four major journals. J Am Board Fam Pract 2001;14:197–200.PubMed Gutknecht DR. Evidence-based advertising? A survey of four major journals. J Am Board Fam Pract 2001;14:197–200.PubMed
10.
Zurück zum Zitat Bero LA, Galbraith A, Rennie D. The publication of sponsors symposiums in medical journals. N Engl J Med 1992; 327:1135–40.PubMedCrossRef Bero LA, Galbraith A, Rennie D. The publication of sponsors symposiums in medical journals. N Engl J Med 1992; 327:1135–40.PubMedCrossRef
11.
Zurück zum Zitat Wilkes MS, Doblin BH, Shapiro MF. Pharmaceutical advertisements in leading medical journals: experts’ assessments. Ann Intern Med 1992;116:912–9.PubMed Wilkes MS, Doblin BH, Shapiro MF. Pharmaceutical advertisements in leading medical journals: experts’ assessments. Ann Intern Med 1992;116:912–9.PubMed
12.
Zurück zum Zitat Gonul F. Promotion of prescription drugs and its impact on the physician’s choice behaviour. J Market 2001;216:79–90.CrossRef Gonul F. Promotion of prescription drugs and its impact on the physician’s choice behaviour. J Market 2001;216:79–90.CrossRef
13.
Zurück zum Zitat Jones MI, Greenfield SM, Bradley CP. Prescribing new drugs: qualitative study of influences on consultants and general practitioners. Br Med J 2001;323:378–81.CrossRef Jones MI, Greenfield SM, Bradley CP. Prescribing new drugs: qualitative study of influences on consultants and general practitioners. Br Med J 2001;323:378–81.CrossRef
15.
Zurück zum Zitat Herxheimer A, Stalsby Lundborg C, Westerholm B. Advertisements for medicines in medical journals; a collaborative international study. Report for director-general of World Health Organisation, Sweden: WHO,1992. Herxheimer A, Stalsby Lundborg C, Westerholm B. Advertisements for medicines in medical journals; a collaborative international study. Report for director-general of World Health Organisation, Sweden: WHO,1992.
Metadaten
Titel
Critical appraisal of apparently evidence-based written advertising in Pakistan
verfasst von
Dileep Kumar Rohra
Muhammad Umair Bashir
Ummey Aymen Khwaja
Muhammad Ressam Nazir
Publikationsdatum
01.06.2008
Verlag
Springer Netherlands
Erschienen in
International Journal of Clinical Pharmacy / Ausgabe 3/2008
Print ISSN: 2210-7703
Elektronische ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-007-9170-7

Weitere Artikel der Ausgabe 3/2008

International Journal of Clinical Pharmacy 3/2008 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.